ESSA Pharma Inc. (EPIX)
| Market Cap | 131.40M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -32.75M |
| Shares Out | 44.09M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 120,054 |
| Open | 3.10 |
| Previous Close | 3.06 |
| Day's Range | 2.96 - 3.10 |
| 52-Week Range | 1.40 - 8.03 |
| Beta | 2.11 |
| Analysts | Buy |
| Price Target | 22.03 (+639.26%) |
| Earnings Date | May 9, 2023 |
About EPIX
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Can... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for EPIX stock is "Buy." The 12-month stock price forecast is $22.03, which is an increase of 639.26% from the latest price.
News
ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , March 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...
ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 13, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022
Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study Phase 1b EPI-7386 monotherapy expansion study in mCRPC pati...
ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 2, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022
SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, CANADA , Dec. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...
ESSA Pharma to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...
J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment
Shares of Essa Pharma Inc. EPIX, +1.38% fell 28.6% in premarket trading on Monday after the company said Johnson & Johnson JNJ, +1.49% suspended enrollment in a Phase 1 clinical trial for Essa's exper...
ESSA Provides an Update on its Clinical Collaboration with Janssen
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Oct. 31, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...
ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Oct. 26, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...
Why Is ESSA Pharma (EPIX) Stock Up 156% Today?
ESSA Pharma (NASDAQ: EPIX) stock is flying higher on Wednesday following the release of data from a Phase 1/2 study of EPI-7386. EPI-7386 is a drug in development for the treatment of metastatic cast...
Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat
EPI-7386 in combination with enzalutamide was safe and well-tolerated at the doses tested with clinically relevant drug exposures and deep and durable prostate specific antigen ("PSA") reductions obse...
ESSA Pharma Appoints Philip Kantoff to its Board of Directors
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Sept. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on dev...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Aug. 4, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...
ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development
EPI-7386 was safe and well-tolerated at all dose levels and schedules tested with plasma target concentrations achieved and clinically important efficacy signals Conference Call and Webcast Today at 5...
ESSA Pharma to Present at 2022 Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , June 2, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , May 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developin...
ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , April 26, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on dev...
ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders
Orally bioavailable ANITAC™ degraders can eliminate full length, mutant and splice variant forms of AR that are expressed in castration-resistant prostate cancer (CRPC) patients ANITAC degraders inhib...
ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference
South San Francisco, California and Vancouver, Canada, March 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 9, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on devel...
ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting
First presentation of preclinical data for ESSA's androgen receptor (AR) N-terminal domain degraders ANIT en bAsed Chimera (ANITAC™) degraders degrade full length, mutant and splice variant forms of A...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021
HOUSTON, Texas and VANCOUVER, Canada, Feb. 3, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therap...
ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
HOUSTON and VANCOUVER, BC, Jan. 19, 2022 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021
VANCOUVER, Canada and HOUSTON, Texas, Nov. 18, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel thera...
ESSA Pharma to Participate in Three Upcoming Investor Conferences
VANCOUVER, Canada and HOUSTON, Texas, Nov. 8, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therap...